MariMed CCO exercises 250,000 RSUs, withholds shares

MariMed Inc. reports that Chief Commercial Officer Ryan Crandall exercised 250,000 Restricted Stock Units into common stock on June 15, 2026, from a December 15, 2025 RSU grant.

Rhea-AI Filing Summary

MariMed Inc. reports that Chief Commercial Officer Ryan Crandall exercised 250,000 Restricted Stock Units into common stock on June 15, 2026, from a December 15, 2025 RSU grant. To cover tax obligations, 86,626 shares were withheld at $0.069 per share. Following these transactions, he directly holds 1,102,803 common shares, with remaining RSUs under this grant scheduled to vest in equal installments on December 15, 2026, June 15, 2027 and December 15, 2027.

Insider Trade Summary

250,000 shares exercised/converted

Exercise 3 txns

Insider Crandall Ryan

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units (RSU)	250,000	$0.00	$0.00
Exercise	Common stock	250,000	$0.00	$0.00
Exercise Price or Tax Liability	Common stock	86,626	$0.069	$6K

Holdings After Transaction: Restricted Stock Units (RSU) — 750,000 contracts (Direct); Common stock — 1,102,803 shares (Direct)

Footnotes (3)

1. F1. RSUs convert to shares of common stock on a one-for-one basis.
2. F2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.
3. F3. The RSUs were granted on December 15, 2025; the remaining RSUs under this grant will vest in three equal installments on each of December 15, 2026, June 15, 2027 and December 15, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Key Figures

RSUs exercised: 250,000 shares Shares withheld for taxes: 86,626 shares Tax withholding price: $0.069 per share +2 more

5 metrics

RSUs exercised 250,000 shares Restricted Stock Units converted to common stock on June 15, 2026

Shares withheld for taxes 86,626 shares Common stock withheld to satisfy tax obligations on RSU vesting

Tax withholding price $0.069 per share Per-share value applied to shares withheld for tax obligations

Post-transaction direct holdings 1,102,803 shares Directly held MariMed common stock after the reported transactions

RSU grant date December 15, 2025 Grant date of RSUs that partially vested on June 15, 2026

Key Terms

Restricted Stock Units (RSU), tax withholding obligations, vesting

3 terms

Restricted Stock Units (RSU) financial

"Restricted Stock Units (RSU) convert to shares of common stock"

tax withholding obligations financial

"shares of common stock withheld by the Issuer to satisfy tax withholding obligations"

vesting financial

"in connection with the vesting of RSUs"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What RSUs did MariMed (MRMD) CCO Ryan Crandall exercise?

Ryan Crandall exercised 250,000 Restricted Stock Units into MariMed common stock on June 15, 2026. These RSUs were part of a grant awarded on December 15, 2025 and convert into common stock on a one-for-one basis as they vest.

How many MariMed (MRMD) shares were withheld for Ryan Crandall's taxes?

The company withheld 86,626 shares of MariMed common stock at $0.069 per share to satisfy Ryan Crandall’s tax withholding obligations. These shares relate to the vesting of his RSUs and are a non-market disposition back to the issuer.

What is Ryan Crandall's MariMed (MRMD) shareholding after this transaction?

After the reported RSU vesting and related tax withholding, Ryan Crandall directly holds 1,102,803 shares of MariMed common stock. This figure reflects his post-transaction position as Chief Commercial Officer following the June 15, 2026 equity transactions.

When will the remaining RSUs for MariMed (MRMD) CCO Ryan Crandall vest?

Remaining RSUs from the December 15, 2025 grant will vest in three equal installments on December 15, 2026, June 15, 2027, and December 15, 2027. Each vesting converts RSUs into MariMed common stock on a one-for-one basis.

What type of transactions are reported in this MariMed (MRMD) Form 4 for Ryan Crandall?

The Form 4 reports an RSU exercise converting 250,000 units to common stock and a tax-withholding disposition of 86,626 shares. Together they reflect equity compensation vesting rather than an open-market purchase or sale of MariMed shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Crandall Ryan

(Last) (First) (Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD MASSACHUSETTS 02062

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	06/15/2026		M		250,000	A	$0(1)	1,189,429	D
Common stock	06/15/2026		F		86,626(2)	D	$0.069	1,102,803	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units (RSU)	(1)	06/15/2026		M			250,000	(3)	(3)	Common Stock, par value $.001 per share	250,000	$0	750,000	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. Reflects shares of common stock withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of RSUs.

3. The RSUs were granted on December 15, 2025; the remaining RSUs under this grant will vest in three equal installments on each of December 15, 2026, June 15, 2027 and December 15, 2027, in accordance with the terms of an award agreement between the Issuer and the Reporting Person.

Remarks:

	/s/ Ryan Crandall	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)